Abstract The oncology community has increased efforts to inform survivors about long-term risks and planned follow-up after cancer treatment. Survivorship care plans (SCPs) have been recommended since 2005, yet the benefits of implementation are only now being emphasized. SCPs are hypothesized to enhance patient knowledge. The Wisconsin Survey of Diagnosis and Management in Breast Cancer (WiSDOM-B) was developed to measure changes in breast cancer survivor knowledge pre-and postdelivery of an SCP. The WiSDOM-B was developed with input from oncologists (medical, radiation, and surgical), patient advocates, cancer survivors, and survey design experts. Initially, nine patients evaluated survey content, and modifications were made to enhance clarity. Subsequently, 38 patients were enrolled in a randomized pilot trial assessing SCP impact on knowledge of diagnosis, treatment, late effects, and follow-up (WiSDOM-B) and satisfaction with knowledge (existing survey). The WiSDOM-B was developed using feedback from multiple stakeholders. Baseline knowledge was poor and remained stable in the control arm. There was a suggestion of increased survivor knowledge following receipt of SCPs in the intervention arm (68.4 vs. 74.4 %). Change was not statistically significant compared with the control arm. Despite knowledge deficits, baseline satisfaction with knowledge was high for both groups, with 100 % of patients being satisfied/very satisfied with information provided. Satisfaction did not change significantly following SCP receipt. The WiSDOM-B assesses survivor knowledge of cancer diagnosis, treatment, follow-up, and side effects. It will be a useful tool for future studies assessing the impact of care plans on survivor knowledge.
Introduction
The Institute of Medicine (IOM) report "Lost in Transition" acknowledged that many cancer survivors do not receive recommended, routine care following active treatment [5] . Care for cancer survivors remains suboptimal [1, 2] . Providing adequate care will become ever more challenging as the number of survivors continues to increase [3] , and leads to a demand for oncologists expected to exceed the available supply [4] . The IOM recommends providing cancer treatment summaries and survivorship care plans (SCPs) to improve provider-survivor communication and coordination of care [5] . Studies indicate that survivors desire SCPs [6] and report greater satisfaction when one is provided [7] . However, little research has been conducted to validate SCPs as a tool to improve providersurvivor communication or survivor outcomes. To our knowledge, two randomized trials of SCPs have been performed. Both studies were conducted within the Canadian health system, and neither demonstrated a positive impact [8, 9] . These studies have been criticized because the outcomes assessed (distress, functioning, and well-being) are not directly targeted by SCPs [10] . Despite lacking evidence for efficacy, several national organizations recommend delivery of SCPs to all survivors [11, 12] , and SCP delivery has been set as a quality measure by the Commission on Cancer [12] . Breast cancer represents nearly one-quarter of the cancer survivor population, making these survivors an ideal population for initial evaluation [12] .
A critical element appears to be missing from the SCP debate: do SCPs impact survivor knowledge? Survivor knowledge of diagnosis and treatments received is poor. For instance, only 42 % of breast cancer survivors receiving doxorubicin could identify that they had received this medication [8] . Findings like this are concerning in light of the growing understanding that cancer treatments may lead to chronic or late side effects [13, 14] . In childhood cancers, patients lack knowledge of individual risk for late complications [15] . Little data exists regarding breast cancer survivor's knowledge of risk for late effects. A survivor's long-term health may depend on understanding not only their diagnosis and treatment but also potential long-term adverse effects of treatments received and recommendations for future cancer screening [5] . Nissen et al. recently demonstrated that patients who received a SCP improved their knowledge of stage of disease, morphology, ER/PR status, and receipt of either hormone therapy or doxorubicin [8] . Although not randomized, this study supports the hypothesis that SCPs may improve knowledge. However, Nissen et al. focused on knowledge of diagnosis and treatment, without evaluating awareness of specific side effects or future screening recommendations. Curcio et al. assessed survivorship knowledge, including late effects and follow-up, after SCP receipt. This study assessed if patients recalled hearing about side effects and recommended followup, rather than asking them to identify specific effects for which they are at risk [16] . We hypothesize that SCPs will increase survivor knowledge of features of tumors at diagnosis, treatments, as well as late side effects, and recommended follow-up. This increased knowledge would have the potential to translate into improved health outcomes. However, a survey to assess survivor knowledge is needed to evaluate the impact of SCPs on these four components of care for breast cancer survivors.
The aim of this study was the development and evaluation of a survey to assess breast cancer survivor knowledge of initial diagnosis, types of treatments received, potential longterm complication, and follow-up recommendations. Here, we report on the design and evaluation of this survey, as well as the use of this survey in a pilot randomized controlled trial investigating the effect of SCPs on survivor knowledge.
Methods

Survey Development and Variables
We reviewed the literature and conference proceedings for samples of surveys assessing survivor knowledge of diagnosis and treatment. Existing surveys did not include questions pertaining to long-term complications or follow-up recommendations [17] [18] [19] [20] . Using these survey references, NCCN and ASCO guidelines, and review of the literature, two oncologists created questions addressing knowledge of diagnosis, treatments received, late complications, and expected follow-up. Questions were reviewed and revised for content and thoroughness based on input from the following focus groups: physicians (medical, surgical, and radiation oncologists), patient advocates, and the research team. Next, the Survey Research Shared Service (SRSS) reviewed and revised questions. SRSS provides expertise and experience in the design and implementation of cancer-related surveys [21] . As part of their review, SRSS administered the survey to a group of patient advocates and a group of cancer survivors. SRSS evaluated survey understandability, thoroughness, sensitivity of language, time spent on survey completion, and participant impressions of the survey. Based on feedback, the survey was revised and administered to a development cohort of patients. SRSS assessed the ease of administering the survey online and evaluated content and understandability in the development cohort by verbal feedback from participants. Time spent on survey was captured by the online survey tool. Following assessment in the development cohort, the survey (Wisconsin Survey of Diagnosis and Management in Breast Cancer, WiSDOM-B) was finalized for use in a pilot randomized controlled trial of SCP impact on survivor knowledge (test cohort). The Preparing for Life as a New Survivor (PLANS) survey, developed at the University of Michigan, was utilized to evaluate survivor satisfaction with (1) own knowledge of diagnosis, treatment and side effects and (2) communication with the cancer team regarding diagnosis, treatment, and side effects [22] . PLANS questions assess the level of agreement with statements regarding satisfaction with a 4-point scale (strongly disagree, somewhat disagree, somewhat agree, strongly agree) for each statement.
This study was approved by the local institutional review board and conducted in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. All participants in the test and development cohorts were consented prior to enrollment. Participants received SCPs upon study completion, and participants in the test cohort also received a small monetary compensation.
Patient Population All breast cancer patients were enrolled at a clinic visit with medical oncology. Patients were eligible if they met the following criteria: diagnosed with stage 0-III breast cancer, had completed active treatment, and had an email account. Active treatment was defined as surgery, chemotherapy, or radiation; patients could still be receiving adjuvant endocrine or HER2-targeted therapy. Patients were excluded for breast cancer diagnosis >5 years prior to enrollment, more than one primary breast cancer, local recurrence (due to concern for confusion regarding question content), metastatic breast cancer, or previous receipt of a SCP.
Development Cohort The purpose of the development cohort was to assess ease of online survey completion and clarity of questions. Survey 1 (WiSDOM-B + PLANS) was administered online by SRSS in the clinic. Following survey 1 administration, SRSS conducted verbal assessments regarding content and clarity of the surveys. Based on these assessments, minor modifications were made to the WiSDOM-B prior to the second administration. Four weeks later, survivors were invited by e-mail to complete survey 2 (the revised WiSDOM-B + PLANS). Survey 2 was taken online outside of the clinic. Participants were asked to complete the survey without using any references or help from others. The average time to complete each survey was recorded.
Correct responses for diagnosis and treatment were abstracted from a medical chart. A dictionary of potential toxicity was developed by three oncologists and reviewed by our Breast Cancer Disease-Oriented Working Group (see Supplementary Material 1). After the development cohort completed survey 2, the research team reviewed survey questions with high rates of incorrect responses to evaluate for language that could lead to patient errors. Minor modifications to questions were made to enhance clarity and finalize the 22-question WISDOM-B survey for use in the test cohort (see Supplementary Material 2).
Test Cohort
The purpose of the test cohort was to assess for change in knowledge following receipt of an SCP. See Fig. 1 for the study schema. Participants completed survey 1 (WiSDOM-B + PLANS) online. Participants were then provided access to a secure website containing links to breast cancer resources. Participants were randomized to immediate access of an SCP (experimental group) or following completion of survey 2 (control group) via this website [23] . The SCP provided was an online SCP developed at the University of Wisconsin (UW Ca ncer S ummary and Care P lan or UWCaSP), which contains all of the recommended IOM elements for SCP [5, 24] . Four weeks after accessing the website, participants were invited by e-mail to complete survey 2 (WiSDOM-B + PLANS).
Correct responses for the WiSDOM-B questions were identified as previously described for the development cohort. A 32-point system was used for grading. Relatively similar emphasis was placed on diagnosis, treatment, and side effects with allocation of 8 points, 14 points, and 10 points, respectively (Supplementary Material 2). Questions on side effects were worth 3 points, with 1/2 point subtracted for each incorrect side effect. For example, the correct list of side effects for a postmenstrual participant receiving chemotherapy with doxorubicin, cyclophosphamide, and paclitaxel was determined to be heart problems, leukemia, and neuropathy; if the patient selected leukemia, neuropathy, and infertility, a full point would be subtracted (1/2 point each for including infertility and excluding heart problems) giving a score of 2 out of 3 possible points.
Statistical Analysis Patient characteristics (age, cancer stage, diagnosis, and treatment received) were summarized for the development cohort and the test cohort (control and intervention groups). Medians and ranges were calculated for continuous variables, and counts and percentages were calculated for categorical variables. For the development cohort, median times to complete the WiSDOM-B and PLANS surveys were calculated. For the test cohort, means and standard deviations of absolute WiSDOM-B scores (out of 32) were calculated and summarized at survey 1 (baseline) for all participants in aggregate and by treatment group for survey 2 for participants completing both surveys. Changes in score from survey 1 to 2 were calculated for the control and intervention groups; the difference was calculated and tested using an ANCOVA model with baseline score as a covariate. This analysis was powered to detect a 10 % difference in survivor knowledge or a difference of 4 points on the 32-point scale. Counts and percentages of correct answers for selected WiSDOM-B questions were also summarized. Mean PLANS scores for satisfaction with own knowledge and with cancer team communication in the areas of diagnosis, treatment, and follow-up were summarized. Paired Wilcoxon signed rank tests were used to test for changes in satisfaction scores between surveys 1 and 2.
Results
Survey Development Process
To develop the WiSDOM-B, questions were modified based on feedback from clinicians, patient advocates, breast cancer survivors, research coordinators, the SRSS, and study participants in the development cohort. See Table 1 for examples of question modifications. Table 2 . For the test cohort, the median age was 57, and the majority of patients received therapies besides surgery, with 53 % receiving chemotherapy, 74 % radiation, and 84 % endocrine therapy. Thirty-five (92 %) of the test cohort participants accessed their SCPs. Two patients did not access their SCP online, and one patient who developed intercurrent metastatic disease did not have a SCP posted. Survey 1 was completed by all 38 participants, and survey 2 was completed by 33 (87 %) participants.
Demographics and Participation
Time Required for Survey Completion Testing in the development cohort established that the WiSDOM-B could be administered online in a reasonable time frame. The median time required to complete the WiSDOM-B alone was 12 min, and the median time to complete both the WiSDOM-B and PLANS was 19 min as assessed via the survey data collection software.
Test Cohort Knowledge and Satisfaction For the 38 test cohort participants, the mean survey 1 (baseline) WiSDOM-B score was 21.7±4.6 (68±14 %). Scores ranged from 11.0 to 29.0 (34-91 %) out of a total possible score of 32. For the 33 participants completing both surveys 1 and 2, the mean scores in the intervention group (n =16) for survey 1 and 2 were 21.9 4) . The mean change in knowledge for the intervention group was +1.9 (SD 2.3) vs. +0.8 (SD 1.5) for the control group. This gave a between-group difference of change in a score of +1.1 in favor of the intervention group, though this difference was not statistically significant (p =0.10) (Fig. 2) .
In the final analysis, we did not score the question regarding next mammogram as many patients were off by 1 month, which was not felt to be clinically significant. For future use, this question was modified to ask the time frame for the next mammogram (ex. within 1 year). Of the question categories in the WISDOM-B, patients had greater difficulty identifying risks or side effects than characteristics of diagnosis and treatment. For example, participants had difficulty identifying that breast pain, lymphedema, and skin changes were potential side effects of surgery (Table 3) .
At baseline, mean scores of satisfaction with own knowledge of diagnosis, treatment, and follow-up were 3.7, 3.6, and 3.6, respectively (1=strongly disagree and 4=strongly agree with the statement "I am satisfied with what I currently know about…"). Mean scores of satisfaction with cancer team's communication regarding diagnosis, treatment, and followup were 3.9, 3.8, and 3.8, respectively. There were no significant differences between these baseline scores and scores on follow-up (all p >0.09).
Discussion
Previous surveys in the survivorship literature have focused on patient knowledge regarding characteristics of diagnosis and cancer treatment. Knowledge of long-term toxicities and follow-up are also needed to evaluate SCP impact [8, 9] . The findings from the WiSDOM-B are consistent with the reported literature that survivors have poor baseline knowledge of diagnosis and treatment details [17] . Although Curcio et al. previously described that patients could not recall hearing about potential late side effects, our findings clarify this knowledge deficit with evaluation of specific late toxicities. For example, less than half of participants were able to identify low bone density as a long-term side effect of endocrine therapy. In this case, the knowledge deficit may result in patients not receiving bone mineral density evaluation and delayed initiation of bisphosphonate therapy, which could ultimately lead to fractures. Without understanding of chronic or future side effects, patients are at risk for delayed recognition and treatment of side effects from prior therapy, translating into impact on quality of life and potentially increased morbidity or even mortality.
To our knowledge, the WiSDOM-B is the first survey to include all major components of survivor knowledge: characteristics of cancer at diagnosis, treatments rendered, long-term toxicities and side effects, and follow-up recommendations. Although we did not score the question regarding next mammography from this evaluation, we will include this important (84) 16 (84) a Includes two patients with stage 0 disease after neoadjuvant chemotherapy follow-up recommendation on further testing. This survey was developed using the literature and current guidelines, with added multidisciplinary input from physicians, patient advocates, survivors, research personnel, survey development experts, and a development cohort of nine breast cancer patients. The use of survivor input from the development cohort is a clear strength, as reflected by several specific changes to question language described in Table 1 . This comprehensive review, with involvement of multiple stakeholders, not only improves the clarity and content of the evaluation but also enhances the utility of the survey. For example, our stakeholders identified that stage may change during the time course of cancer diagnosis, particularly for patients receiving neoadjuvant chemotherapy. It is unclear how a survivor with a clinical stage III (cT3 cN2 cM0) and a pathologic stage 0 (ypT0 ypN0 cM0) breast cancer should respond when asked "What is the stage of your cancer?". This is a source of potential confusion on the survey used by Nissen et al. Furthermore, we attempted to limit questions about diagnosis and treatment to those with clinical relevance-in other words, what an oncologist might ask a new patient who arrives without accompanying records. Because our stakeholders noted that many survivors know the regimen name (e.g., CMF) but not the drug names (cyclophosphamide, methotrexate, and fluoruracil), we incorporated a regimen question. This survey (WiSDOM-B) can be administered online, making it accessible, easily retrievable, and decreasing data entry costs for a research study or quality improvement initiative. Online surveys might also be incorporated into electronic medical records to provide support for discussion among care providers and patients, both in research and routine clinical practice. We employed a randomized design, as it allowed us to control for the effect of administering the survey itself, unlike the reported study by Nissen et al. In the control group, most participants demonstrated at least some improvement in knowledge. This may reflect participant access to online breast cancer references via the study website or other knowledge-seeking behavior prompted simply by asking the survey 1 questions. In the intervention group, there was a suggestion towards greater improvement in survivor knowledge after receipt of the UWCaSP (the study was not powered to detect a difference of less than 10 %.) A larger number of patients may be required to detect a smaller but still clinically meaningful difference. However, the positive trend from our data supports the conclusion by Nissen et al. that SCPs enhance knowledge [17] . Further analysis of a larger randomized sample is required to better characterize whether knowledge (as measured by the WiSDOM-B) increases following SCP receipt. We are currently conducting a multicenter, randomized trial assessing knowledge pre-and post-SCP (half the participants will receive the UWCaSP and the other half will receive Journey FORWARD) [25] using the WiSDOM-B.
We emphasized personal risk for side effects over the general survivor population risks. We fell each survivor should have access to individualized information, concentrated on her own risk related to her diagnosis and the specific therapies she received, rather than having to remember which out of a long list of potential side effects apply to her particular situation. For example, even though infertility may be a potential effect of chemotherapy, a postmenopausal woman could not experience this side effect and should not be counseled about this risk. By focusing on the potential side effects relevant for a particular patient, we aim to minimize knowledge burden and the influence of outside sources and emphasize provider-survivor communication via SCPs.
The WiSDOM-B has several limitations. First, we excluded patients with recurrent and bilateral breast cancer. These exclusion criteria were necessary for initial survey development to ensure question clarity. A revised version of the For side effects, the number of participants giving correct answers for all questions related to that side effect is provided (e.g., side effect of surgery, side effect of chemotherapy, etc.)
WiSDOM-B has been created to allow these survivors to participate in future studies (Supplementary Material 2) . Second, our pilot population consisted entirely of Englishspeaking women. Third, all women had access to e-mail. This may have selected for a better-educated population, and online surveys might limit the ability to enroll participants without computer access. Further assessment would be needed to establish use in paper format. Fourth, the optimal time for delivery of an SCP remains unclear and our study included women at very different distances from diagnosis. The median time from diagnosis was 19.7 months. It is possible that the impact might be larger (or smaller) for patients who receive their care plan immediately after completion of therapy. Fifth, SCPs were not verbally reviewed with patients, potentially changing the impact of the SCP intervention. A final limitation is potential controversy regarding attribution of side effects to specific therapies. The correct responses to our survey were based on a side effect catalog developed by our research team. Other providers might identify additional side effects, use different terminology in communication with patients, or disagree with our interpretation. In the setting of SCP evaluation, this limitation may be negligible as the correct answers could be reset based on information as provided by SCPs.
The PLANS survey demonstrated that most patients were very satisfied with their knowledge level and the information provided by their oncologists. Given the high baseline satisfaction, this endpoint may not improve with SCP receipt. There was a discrepancy between survivor satisfaction with knowledge (97 % were satisfied/very satisfied with their own knowledge) and actual ability to correctly identify key elements of diagnosis, treatment, and risk (median 67 % correct on the WiSDOM-B). This data suggests that survivors are not aware of knowledge deficits, contributing to failure to seek additional information about their cancer. This knowledge deficit limits the ability to recognize complications of therapy or seek appropriate screening. Education of survivors will be important in maximizing their ability to receive appropriate care after diagnosis.
Conclusions
The WiSDOM-B survey is a tool for assessing breast cancer survivor knowledge of the characteristics of cancer diagnosis, treatments rendered, potential side effects and long-term toxicities, and follow-up recommendations. This tool can be used in the evaluation of interventions aimed at improving care for survivors, including both research and quality improvement initiatives. The implementation of SCPs is associated with a suggestion of enhanced survivor knowledge using the WiSDOM-B.
